Ocular Therapeutix (OCUL) reported Monday a Q4 net loss of $0.29 per diluted share, narrower than its loss of $0.35 per share a year earlier.
Analysts polled by FactSet expected a loss of $0.25.
Revenue for the quarter ended Dec. 31 was $17.1 million, up from $14.8 million a year earlier.
Analysts surveyed by FactSet expected $17.2 million.
As of Dec. 31, the company said it had $392.1 million in cash and cash equivalents on hand, and expected it could fund operations into 2028.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。